Results 231 to 240 of about 29,580 (292)

Topical 1.5% ruxolitinib cream for facial refractory segmental vitiligo: A retrospective single-center study. [PDF]

open access: yesJAAD Int
Huang H   +12 more
europepmc   +1 more source

Treatment persistence and overall survival in myelofibrosis treated with ruxolitinib were not affected by the covid-19 pandemic, despite the reduced starting dose: Analysis of AIFA registries. [PDF]

open access: yesAnn Hematol
Breccia M   +12 more
europepmc   +1 more source

Clinical and hematological factors predicting the effectiveness of ruxolitinib in primary and secondary myelofibrosis. Results of a prospective single-center study

open access: diamond
Olga Vinogradova   +9 more
openalex   +1 more source

Impact Of Prognostically Detrimental Mutations (ASXL1, EZH2, SRSF2, IDH1/2) On Outcomes In Patients With Myelofibrosis Treated With Ruxolitinib In COMFORT-II

open access: green, 2013
Paola Guglielmelli   +15 more
openalex   +2 more sources

Discovery of molecularly-informed therapeutic strategies for mature T-cell leukemias and lymphomas. [PDF]

open access: yesBlood Adv
Schmidt N   +19 more
europepmc   +1 more source

Table S6 from Abatacept/Ruxolitinib and Screening for Concomitant Respiratory Muscle Failure to Mitigate Fatality of Immune-Checkpoint Inhibitor Myocarditis

open access: gold
Joe‐Elie Salem   +42 more
openalex   +1 more source

Home - About - Disclaimer - Privacy